Growth, Systemic Safety, and Efficacy During 1 Year of Asthma Treatment With Different Beclomethasone Dipropionate Formulations: An Open-Label, Randomized Comparison of Extrafine and Conventional Aerosols in Children
Authors:
- Søren PedersenSPSøren Pedersen
- on behalf of the Pediatric Study GroupOGon behalf of the Pediatric Study Group
- 1 June 2002
- journal article
- clinical trial
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 109 (6) , e92
Abstract
Objective. To assess the long-term safety of hydrofluoroalkane 134a (HFA)-beclomethasone dipropionate (BDP) extrafine aerosol administered by the Autohaler compared with chlorofluorocarbon (CFC)-BDP administered by a press-and-breathe metered-dose inhaler (pMDI) and spacer (+S) in the treatment of children with asthma. Methods. This 12-month, open-label, randomized, multicenter study enrolled 300 children who were aged 5 to 11 years and had well-controlled asthma on inhaled CFC-BDP or budesonide; 256 patients were using doses within the recommended range (200–400 μg) and were analyzed separately. Patients were randomized in a 1:3 ratio to continue on CFC-BDP+S at approximately the same dose as they were using before study entry or switch to HFA-BDP at half the daily dose. Results. Asthma control was well maintained in the HFA-BDP group as evidenced by lung function tests and asthma symptoms compared with CFC-BDP+S at approximately twice the dose. There were no significant differences between the HFA-BDP 100 to 200 μg and CFC-BDP+S 200 to 400 μg treatment groups in mean change from baseline in height (5.23 cm vs 5.66 cm at month 12, respectively) or mean growth velocity from day 1 to month 12 (5.27 cm/y vs 5.71 cm/y, respectively). There were no significant differences between groups in adrenal function tests or markers of bone metabolism. Conclusions. In this long-term study in children with asthma, extrafine HFA-BDP provided long-term maintenance of asthma control at approximately half the dose compared with CFC-BDP+S. There were no clinically meaningful differences between HFA-BDP extrafine aerosol and conventional CFC-BDP+S with regard to growth or other systemic effects.Keywords
This publication has 19 references indexed in Scilit:
- Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosolAnnals of Allergy, Asthma & Immunology, 2001
- Effect of Long-Term Treatment with Inhaled Budesonide on Adult Height in Children with AsthmaNew England Journal of Medicine, 2000
- Long-Term Effects of Budesonide or Nedocromil in Children with AsthmaNew England Journal of Medicine, 2000
- Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant☆☆☆★Journal of Allergy and Clinical Immunology, 1999
- Hydrofluoroalkane-134a Beclomethasone Dipropionate, 400 μg, Is as Effective as Chlorofluorocarbon Beclomethasone Dipropionate, 800 μg, for the Treatment of Moderate AsthmaChest, 1999
- Low-dose adrenocorticotropin test reveals impaired adrenal function in patients taking inhaled corticosteroidsThe Journal of Clinical Endocrinology & Metabolism, 1995
- Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic childrenRespiratory Medicine, 1994
- Distinctions between short- and long-term human growth studiesActa Paediatrica, 1993
- International consensus report on diagnosis and management of asthmaAllergy, 1992
- Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty.Archives of Disease in Childhood, 1976